ALXO - ALX Oncology Holdings Inc

-

$undefined

N/A

(N/A)

ALX Oncology Holdings Inc NASDAQ:ALXO ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.

Location: | Website: alxoncology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-28.64M

Cash

156.7M

Avg Qtr Burn

-33.83M

Short % of Float

46.25%

Insider Ownership

1.92%

Institutional Own.

-

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evorpacept (ALX148) + Keytruda Details
Cancer, Platinum-resistant ovarian cancer

Phase 2

Data readout

Phase 2

Data readout

Evorpacept (ALX148) + Keytruda Details
Head and neck cancer, Cancer

Phase 2

Data readout

Evorpacept + cetuximab + pembrolizumab Details
Cancer, Metastatic colorectal cancer

Phase 2

Update

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued

Evorpacept (ALX148) + Venetoclax Details
Cancer, Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued